Session Details

Speakers, titles, times, and locations of ASGCT presentations

Detailed Program

391: An Evolved AAV Variant Enables In Vivo CAR-T Cell Generation, Tumor Cytotoxicity, and B Cell Elimination

Disclosures:   L. Ma: 1; Commercial Interest i.e. Company X; Westlake Genetech. 1; What was received? i.e. Honorarium; Stock. 1; For what role? i.e. Speaker; Scientific founder and board member.

Related Abstract

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.